Peritoneovenous shunts palliate malignant ascites

James A. Edney, Adella Hill, Deanna Armstrong

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Fifty-five peritoneovenous shunts (PVS) were implanted in 45 patients (29 LeVeen and 26 Denver shunts). Seventy-five percent of patients experienced relief of symptoms referable to their ascites. The mean survival time post-shunt placement was 33 weeks; however, considerable variation was noted in survival times for the various tumor types (pancreas 7 weeks, ovary 71 weeks). Significant alterations in coagulation parameters consistent with subclinical disseminated intervascular coagulation (DIC) were present in all patients with functioning shunts. These coagulation changes have proven reliable indicators of shunt patency. Shunt revision was necessary in 18 percent of patients. No significant difference in shunt patency was detected when Denver and LeVeen shunts were compared. This experience indicates that PVS offers effective palliation without undue morbidity for malignant ascites. The best results can be expected in those patients with ovarian and breast primary tumors. Because of the short time from onset of disabling ascites until death, PVS is not indicated in the majority of patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)598-601
Number of pages4
JournalThe American Journal of Surgery
Volume158
Issue number6
DOIs
StatePublished - Dec 1989

Fingerprint

Peritoneovenous Shunt
Ascites
Pancreatic Neoplasms
Pancreas
Ovary
Survival Rate
Breast Neoplasms
Morbidity
Survival

ASJC Scopus subject areas

  • Surgery

Cite this

Peritoneovenous shunts palliate malignant ascites. / Edney, James A.; Hill, Adella; Armstrong, Deanna.

In: The American Journal of Surgery, Vol. 158, No. 6, 12.1989, p. 598-601.

Research output: Contribution to journalArticle

Edney, James A. ; Hill, Adella ; Armstrong, Deanna. / Peritoneovenous shunts palliate malignant ascites. In: The American Journal of Surgery. 1989 ; Vol. 158, No. 6. pp. 598-601.
@article{d9821ce0f6534959a45011b9d03c75a0,
title = "Peritoneovenous shunts palliate malignant ascites",
abstract = "Fifty-five peritoneovenous shunts (PVS) were implanted in 45 patients (29 LeVeen and 26 Denver shunts). Seventy-five percent of patients experienced relief of symptoms referable to their ascites. The mean survival time post-shunt placement was 33 weeks; however, considerable variation was noted in survival times for the various tumor types (pancreas 7 weeks, ovary 71 weeks). Significant alterations in coagulation parameters consistent with subclinical disseminated intervascular coagulation (DIC) were present in all patients with functioning shunts. These coagulation changes have proven reliable indicators of shunt patency. Shunt revision was necessary in 18 percent of patients. No significant difference in shunt patency was detected when Denver and LeVeen shunts were compared. This experience indicates that PVS offers effective palliation without undue morbidity for malignant ascites. The best results can be expected in those patients with ovarian and breast primary tumors. Because of the short time from onset of disabling ascites until death, PVS is not indicated in the majority of patients with pancreatic cancer.",
author = "Edney, {James A.} and Adella Hill and Deanna Armstrong",
year = "1989",
month = "12",
doi = "10.1016/0002-9610(89)90202-X",
language = "English (US)",
volume = "158",
pages = "598--601",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Peritoneovenous shunts palliate malignant ascites

AU - Edney, James A.

AU - Hill, Adella

AU - Armstrong, Deanna

PY - 1989/12

Y1 - 1989/12

N2 - Fifty-five peritoneovenous shunts (PVS) were implanted in 45 patients (29 LeVeen and 26 Denver shunts). Seventy-five percent of patients experienced relief of symptoms referable to their ascites. The mean survival time post-shunt placement was 33 weeks; however, considerable variation was noted in survival times for the various tumor types (pancreas 7 weeks, ovary 71 weeks). Significant alterations in coagulation parameters consistent with subclinical disseminated intervascular coagulation (DIC) were present in all patients with functioning shunts. These coagulation changes have proven reliable indicators of shunt patency. Shunt revision was necessary in 18 percent of patients. No significant difference in shunt patency was detected when Denver and LeVeen shunts were compared. This experience indicates that PVS offers effective palliation without undue morbidity for malignant ascites. The best results can be expected in those patients with ovarian and breast primary tumors. Because of the short time from onset of disabling ascites until death, PVS is not indicated in the majority of patients with pancreatic cancer.

AB - Fifty-five peritoneovenous shunts (PVS) were implanted in 45 patients (29 LeVeen and 26 Denver shunts). Seventy-five percent of patients experienced relief of symptoms referable to their ascites. The mean survival time post-shunt placement was 33 weeks; however, considerable variation was noted in survival times for the various tumor types (pancreas 7 weeks, ovary 71 weeks). Significant alterations in coagulation parameters consistent with subclinical disseminated intervascular coagulation (DIC) were present in all patients with functioning shunts. These coagulation changes have proven reliable indicators of shunt patency. Shunt revision was necessary in 18 percent of patients. No significant difference in shunt patency was detected when Denver and LeVeen shunts were compared. This experience indicates that PVS offers effective palliation without undue morbidity for malignant ascites. The best results can be expected in those patients with ovarian and breast primary tumors. Because of the short time from onset of disabling ascites until death, PVS is not indicated in the majority of patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0024807003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024807003&partnerID=8YFLogxK

U2 - 10.1016/0002-9610(89)90202-X

DO - 10.1016/0002-9610(89)90202-X

M3 - Article

C2 - 2480068

AN - SCOPUS:0024807003

VL - 158

SP - 598

EP - 601

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 6

ER -